玛巴洛沙韦 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "玛巴洛沙韦" in Chinese language version.

refsWebsite

Global rank Chinese rank

16web.archive.org

1^st place

5fda.gov

447^th place

581^st place

3nih.gov

4^th place

5^th place

2doi.org

2^nd place

23^rd place

2pharnexcloud.com

low place

2europa.eu

68^th place

209^th place

1tga.gov.au

3,984^th place

1,603^rd place

1canada.ca

1,712^th place

3,316^th place

1hres.ca

low place

1huatengsci.com

low place

1worldcat.org

5^th place

12^th place

1semanticscholar.org

11^th place

332^nd place

1jnnews.tv

low place

1roche.com

low place

121jingji.com

low place

1,780^th place

21jingji.com

罗氏就抗流感新药专利起诉石药集团欧意药业. 21经济网. 2022-10-19 [2023-12-17]. （原始内容存档于2023-02-03）.

canada.ca

health-products.canada.ca

Xofluza Product information. Health Canada. 2012-04-25 [2022-05-29]. （原始内容存档于2022-08-12）.

doi.org

Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. December 2018, 160: 109–117. PMID 30316915. doi:10.1016/j.antiviral.2018.10.008 .
O'Hanlon, Ryan; Shaw, Megan L. Baloxavir marboxil: the new influenza drug on the market. Current Opinion in Virology. April 2019, 35: 14–18 [2020-09-28]. ISSN 1879-6265. PMID 30852344. S2CID 73726080. doi:10.1016/j.coviro.2019.01.006. （原始内容存档于2021-11-04）.

europa.eu

ema.europa.eu

Xofluza EPAR. European Medicines Agency (EMA). 2020-11-09 [2021-01-25]. （原始内容存档于2021-01-30）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

Xofluza Product information. Union Register of medicinal products. [2023-03-03]. （原始内容存档于2023-03-05）.

fda.gov

FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention (新闻稿). U.S. Food and Drug Administration (FDA). 2020-11-23 [2020-11-23]. （原始内容存档于2020-11-23）. 本文含有此來源中屬於公有领域的内容。
FDA approves new drug to treat influenza (新闻稿). U.S. Food and Drug Administration (FDA). 2018-10-24 [2019-10-23]. （原始内容存档于2019-10-24）. 本文含有此來源中屬於公有领域的内容。
New Drug Therapy Approvals 2018 (PDF) (报告). U.S. Food and Drug Administration (FDA). January 2019 [2020-09-16]. （原始内容存档于2020-09-17）. 本文含有此來源中屬於公有领域的内容。

accessdata.fda.gov

Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil). U.S. Food and Drug Administration (FDA). 2018-12-07 [2020-05-10]. （原始内容存档于2020-07-26）. 本文含有此來源中屬於公有领域的内容。
FDA Approval Package for 210854Orig1s001 (PDF). U.S. Food and Drug Administration (FDA). 2019-10-16 [2020-09-30]. （原始内容存档 (PDF)于2021-04-09）. 本文含有此來源中屬於公有领域的内容。

hres.ca

hpr-rps.hres.ca

Summary Basis of Decision (SBD) for Xofluza. Health Canada. 2014-10-23 [2022-05-29]. （原始内容存档于2022-05-31）.

huatengsci.com

en.huatengsci.com

Baloxavir Marboxil for Uncomplicated Influenza: Mechanism of Action & Side Effects. Huateng Pharma. [2020-05-29]. （原始内容存档于2021-02-24）.

jnnews.tv

红星新闻. 新“流感神药”一片200多元？医生提醒：有限制. 济宁新闻网. 2023-12-17 [2023-12-17].

nih.gov

ncbi.nlm.nih.gov

Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. December 2018, 160: 109–117. PMID 30316915. doi:10.1016/j.antiviral.2018.10.008 .
O'Hanlon, Ryan; Shaw, Megan L. Baloxavir marboxil: the new influenza drug on the market. Current Opinion in Virology. April 2019, 35: 14–18 [2020-09-28]. ISSN 1879-6265. PMID 30852344. S2CID 73726080. doi:10.1016/j.coviro.2019.01.006. （原始内容存档于2021-11-04）.

dailymed.nlm.nih.gov

Xofluza- baloxavir marboxil tablet, film coated. DailyMed. 2019-10-28 [2020-01-09]. （原始内容存档于2020-10-28）.

pharnexcloud.com

药通社. 超级抗流感药：玛巴洛沙韦申报/上市情况一览！. 药融云. [2023-12-17].
药融圈. 抗流感新药——玛巴洛沙韦，“重拳出击”，症状改善效果显著！. 药融云. [2023-12-17]. （原始内容存档于2023-05-10）.

roche.com

Xofluza (baloxavir marboxil). Roche. [2023-12-17]. （原始内容存档于2023-05-28）（英语）.

semanticscholar.org

api.semanticscholar.org

O'Hanlon, Ryan; Shaw, Megan L. Baloxavir marboxil: the new influenza drug on the market. Current Opinion in Virology. April 2019, 35: 14–18 [2020-09-28]. ISSN 1879-6265. PMID 30852344. S2CID 73726080. doi:10.1016/j.coviro.2019.01.006. （原始内容存档于2021-11-04）.

tga.gov.au

Xofluza Australian prescription medicine decision summary. Therapeutic Goods Administration (TGA). 2020-03-02 [2020-08-16]. （原始内容存档于2020-03-13）.

web.archive.org

Xofluza Australian prescription medicine decision summary. Therapeutic Goods Administration (TGA). 2020-03-02 [2020-08-16]. （原始内容存档于2020-03-13）.
Xofluza Product information. Health Canada. 2012-04-25 [2022-05-29]. （原始内容存档于2022-08-12）.
Summary Basis of Decision (SBD) for Xofluza. Health Canada. 2014-10-23 [2022-05-29]. （原始内容存档于2022-05-31）.
Xofluza- baloxavir marboxil tablet, film coated. DailyMed. 2019-10-28 [2020-01-09]. （原始内容存档于2020-10-28）.
Xofluza EPAR. European Medicines Agency (EMA). 2020-11-09 [2021-01-25]. （原始内容存档于2021-01-30）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Xofluza Product information. Union Register of medicinal products. [2023-03-03]. （原始内容存档于2023-03-05）.
Baloxavir Marboxil for Uncomplicated Influenza: Mechanism of Action & Side Effects. Huateng Pharma. [2020-05-29]. （原始内容存档于2021-02-24）.
O'Hanlon, Ryan; Shaw, Megan L. Baloxavir marboxil: the new influenza drug on the market. Current Opinion in Virology. April 2019, 35: 14–18 [2020-09-28]. ISSN 1879-6265. PMID 30852344. S2CID 73726080. doi:10.1016/j.coviro.2019.01.006. （原始内容存档于2021-11-04）.
FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention (新闻稿). U.S. Food and Drug Administration (FDA). 2020-11-23 [2020-11-23]. （原始内容存档于2020-11-23）. 本文含有此來源中屬於公有领域的内容。
Xofluza (baloxavir marboxil). Roche. [2023-12-17]. （原始内容存档于2023-05-28）（英语）.
FDA approves new drug to treat influenza (新闻稿). U.S. Food and Drug Administration (FDA). 2018-10-24 [2019-10-23]. （原始内容存档于2019-10-24）. 本文含有此來源中屬於公有领域的内容。
Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil). U.S. Food and Drug Administration (FDA). 2018-12-07 [2020-05-10]. （原始内容存档于2020-07-26）. 本文含有此來源中屬於公有领域的内容。
FDA Approval Package for 210854Orig1s001 (PDF). U.S. Food and Drug Administration (FDA). 2019-10-16 [2020-09-30]. （原始内容存档 (PDF)于2021-04-09）. 本文含有此來源中屬於公有领域的内容。
药融圈. 抗流感新药——玛巴洛沙韦，“重拳出击”，症状改善效果显著！. 药融云. [2023-12-17]. （原始内容存档于2023-05-10）.
罗氏就抗流感新药专利起诉石药集团欧意药业. 21经济网. 2022-10-19 [2023-12-17]. （原始内容存档于2023-02-03）.
New Drug Therapy Approvals 2018 (PDF) (报告). U.S. Food and Drug Administration (FDA). January 2019 [2020-09-16]. （原始内容存档于2020-09-17）. 本文含有此來源中屬於公有领域的内容。

worldcat.org

O'Hanlon, Ryan; Shaw, Megan L. Baloxavir marboxil: the new influenza drug on the market. Current Opinion in Virology. April 2019, 35: 14–18 [2020-09-28]. ISSN 1879-6265. PMID 30852344. S2CID 73726080. doi:10.1016/j.coviro.2019.01.006. （原始内容存档于2021-11-04）.